Francis Lo Sells 30,593 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 30,593 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $14.08, for a total transaction of $430,749.44. Following the transaction, the insider owned 291,374 shares of the company’s stock, valued at approximately $4,102,545.92. The trade was a 9.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Francis Lo also recently made the following trade(s):

• On Thursday, March 5th, Francis Lo sold 38,074 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.09, for a total transaction of $574,536.66.
• On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.73, for a total transaction of $1,411,130.70.
• On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.08, for a total transaction of $50,250.00.
• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.50, for a total transaction of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.57, for a total transaction of $1,773,267.30.

Adaptive Biotechnologies Trading Up 5.8%

Shares of Adaptive Biotechnologies stock opened at $13.17 on Friday. The business has a 50-day moving average price of $16.55 and a two-hundred day moving average price of $15.87. Adaptive Biotechnologies Corporation has a 1-year low of $6.68 and a 1-year high of $20.76. The company has a market cap of $2.03 billion, a P/E ratio of -32.92 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same period in the previous year, the business earned ($0.23) EPS. The firm’s revenue was up 51.0% compared to the same quarter last year. Equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ADPT has been the subject of several recent analyst reports. BTIG Research raised their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Institutional Trading of Adaptive Biotechnologies

A number of large investors have recently bought and sold shares of ADPT. Ameriprise Financial Inc. raised its stake in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after acquiring an additional 3,299,635 shares during the last quarter. Westfield Capital Management Co. LP purchased a new stake in Adaptive Biotechnologies in the 4th quarter worth about $65,942,000. Geode Capital Management LLC raised its stake in Adaptive Biotechnologies by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after acquiring an additional 110,825 shares during the period. Finally, State Street Corp raised its stake in Adaptive Biotechnologies by 3.3% in the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after acquiring an additional 102,362 shares during the period. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.